Body Protection Compound-157 (BPC-157) has emerged as one of the most clinically promising therapeutic peptides of the last decade. This pentadecapeptide, consisting of 15 amino acids, was originally isolated from human gastric juice and has since been the subject of extensive preclinical research.
Mechanism of Action
BPC-157 exerts its effects through multiple molecular pathways. Key among these is its interaction with the nitric oxide (NO) system, growth hormone receptors, and several growth factors including VEGF and EGF. The peptide promotes angiogenesis — the formation of new blood vessels — which is critical for delivering nutrients and oxygen to healing tissues.
Clinical Applications
Research has demonstrated BPC-157's effectiveness across a remarkable range of tissues including tendons, ligaments, muscle, bone, cornea, and gastrointestinal epithelium. Its gastroprotective properties are particularly well-documented, with studies showing protection against NSAID-induced damage, inflammatory bowel conditions, and esophageal injury.
In musculoskeletal medicine, BPC-157 has shown accelerated healing of Achilles tendon transections, superior segmental bone defects, and muscle crush injuries in animal models. The translation to human clinical use is supported by its excellent safety profile across all studied populations.
Safety and Tolerability
BPC-157 demonstrates no observed toxicity at therapeutic doses in all reviewed studies. Its origin from the human digestive system suggests a natural biocompatibility that distinguishes it from synthetic pharmaceutical compounds.